Pharma giant Pfizer has agreed to pay $59 million to settle a federal lawsuit accusing a local biopharmaceutical company of paying "kickbacks" ...

Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...

SG Americas Securities LLC cut its position in Biohaven Ltd. (NYSE:BHVN – Free Report) by 45.5% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 9,001 shares ...

Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments ...

Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe ...

The alleged violations occurred before Pfizer bought Biohaven and its migraine treatment three years ago for $11.6 billion.

A coalition consisting of the U.S. Department of Justice, 37 states, and Puerto Rico, filed suit against Biohaven ...

Pfizer Settles Its Subsidiary’s Kickback Allegations for Nearly $60 Million - Pfizer Inc. agreed to pay over $59,746,277 to ...

Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to improper physician remuneration. This settlement marks a pivotal moment in ...

Get Our Latest Research Report on Biohaven Biohaven Price Performance Biohaven stock opened at $38.30 on Friday. The firm’s 50-day moving average is $39.65 and its two-hundred day moving average ...

California Attorney General Announces Nearly $60 Million Settlement Against Pfizer-Owned Pharmaceutical Holding Company, ...